AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY), MannKind Corporation (MNKD): Three New Diabetes Drugs Possibly on the Way Soon

Page 2 of 2

Assuming this approval is granted, how quickly Afrezza makes it to market depends largely on MannKind Corporation (NASDAQ:MNKD)’s efforts at securing a partner. The company has been in talks with multiple prospective organizations for a few months.

Most impact

My view is that all three of these drugs seem likely to become available within the next year or so. I think that each drug can help diabetic patients. Each has a reasonable shot at commercial success.

Which could make the most impact? I’ll go with Afrezza. Yes — past inhaled insulin products haven’t succeeded, but I think MannKind Corporation (NASDAQ:MNKD) has gotten past the issues that plagued those products. An easy-to-take, quick-acting insulin should be appealing to many diabetic patients.

MannKind Corporation (NASDAQ:MNKD) definitely needs a good partner to launch Afrezza in the best way possible. I think the company will find one. Piper Jaffray thinks so as well and pegs peak annual sales for the inhaled insulin at more than $2 billion. If the company is anywhere close to being on target, MannKind shares have plenty of room to run.

The article 3 New Diabetes Drugs Possibly on the Way Soon originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2